Literature DB >> 30582254

Development of high-resolution 3D MR fingerprinting for detection and characterization of epileptic lesions.

Dan Ma1, Stephen E Jones2, Anagha Deshmane3, Ken Sakaie2, Eric Y Pierre4, Mykol Larvie2, Debra McGivney1, Ingmar Blümcke5,6, Balu Krishnan5, Mark Lowe2, Vikas Gulani1, Imad Najm5, Mark A Griswold1, Z Irene Wang5.   

Abstract

BACKGROUND: Conventional MRI can be limited in detecting subtle epileptic lesions or identifying active/epileptic lesions among widespread, multifocal lesions.
PURPOSE: We developed a high-resolution 3D MR fingerprinting (MRF) protocol to simultaneously provide quantitative T1 , T2 , proton density, and tissue fraction maps for detection and characterization of epileptic lesions. STUDY TYPE: Prospective. POPULATION: National Institute of Standards and Technology (NIST) / International Society for Magnetic Resonance in Medicine (ISMRM) phantom, five healthy volunteers and 15 patients with medically intractable epilepsy undergoing presurgical evaluation with noninvasive or invasive electroclinical data. FIELD STRENGTH/SEQUENCE: 3D MRF scans and routine clinical epilepsy MR protocols were acquired at 3 T. ASSESSMENT: The accuracy of the T1 and T2 values were first evaluated using the NIST/ISMRM phantom. The repeatability was then estimated with both phantom and volunteers based on the coefficient of variance (CV). For epilepsy patients, all the maps were qualitatively reviewed for lesion detection by three independent reviewers (S.E.J., M.L., I.N.) blinded to clinical data. Region of interest (ROI) analysis was performed on T1 and T2 maps to quantify the multiparametric signal differences between lesion and normal tissues. Findings from qualitative review and quantitative ROI analysis were compared with patients' electroclinical data to assess concordance. STATISTICAL TESTS: Phantom results were compared using R-squared, and patient results were compared using linear regression models.
RESULTS: The phantom study showed high accuracy with the standard values, with an R2 of 0.99. The volunteer study showed high repeatability, with an average CV of 4.3% for T1 and T2 in various tissue regions. For the 15 patients, MRF showed additional findings in four patients, with the remaining 11 patients showing findings consistent with conventional MRI. The additional MRF findings were highly concordant with patients' electroclinical presentation. DATA
CONCLUSION: The 3D MRF protocol showed potential to identify otherwise inconspicuous epileptogenic lesions from the patients with negative conventional MRI diagnosis, as well as to correlate with different levels of epileptogenicity when widespread lesions were present. LEVEL OF EVIDENCE: 3. Technical Efficacy Stage: 3. J. Magn. Reson. Imaging 2019;49:1333-1346.
© 2018 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  MR fingerprinting; epilepsy; focal cortical dysplasia; nodular heterotopia; quantitative MRI; tuberous sclerosis complex

Year:  2018        PMID: 30582254     DOI: 10.1002/jmri.26319

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  19 in total

Review 1.  Magnetic resonance fingerprinting: an overview.

Authors:  Charit Tippareddy; Walter Zhao; Jeffrey L Sunshine; Mark Griswold; Dan Ma; Chaitra Badve
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-26       Impact factor: 9.236

2.  MR fingerprinting for rapid simultaneous T1 , T2 , and T1 ρ relaxation mapping of the human articular cartilage at 3T.

Authors:  Azadeh Sharafi; Marcelo V W Zibetti; Gregory Chang; Martijn Cloos; Ravinder R Regatte
Journal:  Magn Reson Med       Date:  2020-05-09       Impact factor: 4.668

3.  Three-dimensional high-resolution T1 and T2 mapping of whole macaque brain at 9.4 T using magnetic resonance fingerprinting.

Authors:  Yuning Gu; Lulu Wang; Hongyi Yang; Yun Wu; Kihwan Kim; Yuran Zhu; Charlie Androjna; Xiaofeng Zhu; Yong Chen; Kai Zhong; Xin Yu
Journal:  Magn Reson Med       Date:  2022-02-07       Impact factor: 4.668

4.  Repeatability of MR fingerprinting in normal cervix and utility in cervical carcinoma.

Authors:  Mandi Wang; Jose A U Perucho; Peng Cao; Varut Vardhanabhuti; Di Cui; Yiang Wang; Pek-Lan Khong; Edward S Hui; Elaine Y P Lee
Journal:  Quant Imaging Med Surg       Date:  2021-09

5.  Automated design of pulse sequences for magnetic resonance fingerprinting using physics-inspired optimization.

Authors:  Stephen P Jordan; Siyuan Hu; Ignacio Rozada; Debra F McGivney; Rasim Boyacioğlu; Darryl C Jacob; Sherry Huang; Michael Beverland; Helmut G Katzgraber; Matthias Troyer; Mark A Griswold; Dan Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-30       Impact factor: 11.205

6.  Black Line Sign in Focal Cortical Dysplasia IIB: A 7T MRI and Electroclinicopathologic Study.

Authors:  Yingying Tang; Ingmar Blümcke; Ting-Yu Su; Joon Yul Choi; Balu Krishnan; Hiroatsu Murakami; Andreas V Alexopoulos; Imad M Najm; Stephen E Jones; Zhong Irene Wang
Journal:  Neurology       Date:  2022-05-16       Impact factor: 11.800

7.  Motion-corrected 3D-EPTI with efficient 4D navigator acquisition for fast and robust whole-brain quantitative imaging.

Authors:  Zijing Dong; Fuyixue Wang; Kawin Setsompop
Journal:  Magn Reson Med       Date:  2022-04-28       Impact factor: 3.737

8.  Magnetic resonance fingerprinting residual signals can disassociate human grey matter regions.

Authors:  Shahrzad Moinian; Viktor Vegh; Kieran O'Brien; David Reutens
Journal:  Brain Struct Funct       Date:  2021-10-25       Impact factor: 3.270

9.  Simultaneous T1 , T2 , and T relaxation mapping of the lower leg muscle with MR fingerprinting.

Authors:  Azadeh Sharafi; Katherine Medina; Marcelo W V Zibetti; Smita Rao; Martijn A Cloos; Ryan Brown; Ravinder R Regatte
Journal:  Magn Reson Med       Date:  2021-02-08       Impact factor: 3.737

Review 10.  Rapid MR relaxometry using deep learning: An overview of current techniques and emerging trends.

Authors:  Li Feng; Dan Ma; Fang Liu
Journal:  NMR Biomed       Date:  2020-10-15       Impact factor: 4.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.